Skip to content
Search

Latest Stories

New tool to detect ‘heart risk’ early: The Times

Researchers have developed a new tool to identify people in danger of having a heart attack or stroke much earlier, according to a report in The Times.

The Score2 tool, which experts hailed as a ‘major advance’, is ready for use in the UK and Europe.


It allows doctors to predict who will have a heart attack or stroke in the next decade by combining data including a patient’s age, sex, blood pressure and cholesterol levels, the report said.

“This risk tool is much more powerful and superior to what doctors have used for decades. It will fit seamlessly into current prevention programmes with substantial real-world impact by improving the prevention of cardiovascular diseases across Europe,” Professor Emanuele Di Angelantonio, of the University of Cambridge, who led the research, told The Times.

“Once you are better able to predict the risk you can really discuss the benefits of starting a treatment early on, or making some behavioural changes. By providing a better tool, you’ll possibly be able to make better decisions.

“It could result in a higher number of people suggested to take statins but I think the main aim first of all, before going to treatment, is behavioural change — smoking, diet, lifestyle.”

Score2 replaces a risk calculator created 20 years ago. Unlike its predecessor it predicts someone’s chances of having any heart attack and stroke, not only fatal heart attacks and strokes.

According to experts, the tool is better at picking up risk at younger ages, in people aged between 40 and 60.

The new tool was created using data on nearly 700,000 people taking part in studies across Europe. During ten years of follow-up, 30,000 of them had a ‘cardiovascular event’, including fatal and non-fatal heart attacks and strokes, the report said.

Di Angelantonio said: “We know that for people living in (some countries) in eastern Europe, the risk of developing cardiovascular disease is much higher compared to other parts of Europe, for example in the UK. Reasons for the differences might include differences in lifestyle, average socioeconomic status or pollution levels.

“You really want to tailor your risk prediction to those different settings. Otherwise you can end up over-predicting in one group and under-predicting in the other; not identifying people in one country and finding too many in the other.”

According to the research, a 50-year-old man who smoked, had a systolic [the force at which the heart pumps blood] pressure of 140, total cholesterol of 5.5 and so-called good cholesterol of 1.3 had a 5.9 per cent risk of heart attack or stroke in low-risk countries but a 14 per cent risk in very high-risk countries.

For a woman of the same age the difference ranged from 4.2 per cent to 13.7 per cent.

The UK is considered a low-risk country for cardiovascular problems, after improvements in its death rates from heart attacks and stroke.

GPs in the UK already make similar calculations using a tool known as Qrisk. Di Angelantonio said that it would be up to policymakers whether to recommend Score2.

Dr Lisa Pennells, a researcher at the University of Cambridge British Heart Foundation Centre of Research Excellence, told The Times: “This project was a highly collaborative effort. A key feature is that our calculators are relevant to current day rates of cardiovascular disease in different regions of Europe. Importantly, our methods allow them to be easily updated using routinely collected data in the future to ensure they stay relevant as trends in heart and circulatory diseases change.”

Professor Sir Nilesh Samani, medical director at the British Heart Foundation has said that the new risk tool will be the new gold standard for doctors.

More For You

 RPS honours Professor Tony Avery OBE for excellence in prescribing safety and patient care

Professor Tony Avery OBE

Pic credit: RPS

Professor Tony Avery OBE awarded RPS Honorary Fellowship

The Royal Pharmaceutical Society (RPS) Assembly has awarded an Honorary Fellowship to Professor Tony Avery OBE in recognition of his outstanding contribution to prescribing safety and patient care.

The Honorary Fellowship is given to those who are not eligible for membership of the Society but have either attained a distinction in a particular aspect or aspects of pharmacy, made a distinctive contribution to pharmacy or the RPS, distinguished themselves in any branches of knowledge referred to in the objects of the Society or achieved eminence in public life.

Keep ReadingShow less
US-UK pharmaceutical trade concerns as Liberal Democrat MPs urge protection from Trump tariffs.

UK prime minster Sir Keir Starmer with US president Donald Trump

Pic credit: Getty images

Pharma sector needs protecting from Trump tariffs, warn MPs

A group of Liberal Democrat MPs have written to health secretary Wes Streeting urging him to protect the pharmaceutical industry from US president Donald Trump’s trade war.

The five ministers from Oxfordshire, Olly Glover, Layla Moran, Calum Miller, Charlie Maynard, and Freddie van Mierlo, have warned that Trump’s campaign to raise tariffs has already led to “catastrophic damage”.

Keep ReadingShow less
Pharmacist handing medicine to patient, NHS prescription cost freeze debate

Prescription charge will remain at £9.90

Pic credit: iStock

NPA calls for end to prescription charge after freeze announcement

The National Pharmacy Association (NPA) has asked for prescription charges to be completely removed despite the government announcing today that the charge will be frozen for the first time in three years.

Patients will continue paying £9.90 to collect their medication from a pharmacy.

Keep ReadingShow less
RPS launches new prescribing development programme for pharmacists

From 2026, every newly qualified pharmacist will be an independent prescriber

gettyimages

RPS unveils new training programme to enhance pharmacists’ prescribing skills

The Royal Pharmaceutical Society (RPS) has announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

The initiative comes ahead of the NHS mandate that every newly qualified pharmacist will be an independent prescriber by 2026 — a change set to transform the future of pharmacy practice.

Keep ReadingShow less
Varenicline promotes nicotine vaping cessation in young people

Researchers warn that e-cigarette use can increase risk for nicotine addiction,uptake of combusted tobacco and other substance use.

gettyimages

Anti-smoking pill varenicline may help young people quit vaping, new study suggests

Varenicline — a daily pill already offered through NHS Stop Smoking Services — could also support young people in quitting vaping, new research has suggested.

The medication, proven to be more effective than nicotine replacement gums or patches for smoking cessation, was shown to significantly boost vaping abstinence when combined with behavioural counselling in adolescents and young adults.

Keep ReadingShow less